Magnesium in PDB 5o4v: P.Vivax Nmt with Aminomethylindazole and Quinoline Inhibitors Bound
Enzymatic activity of P.Vivax Nmt with Aminomethylindazole and Quinoline Inhibitors Bound
All present enzymatic activity of P.Vivax Nmt with Aminomethylindazole and Quinoline Inhibitors Bound:
2.3.1.97;
Protein crystallography data
The structure of P.Vivax Nmt with Aminomethylindazole and Quinoline Inhibitors Bound, PDB code: 5o4v
was solved by
J.A.Brannigan,
A.J.Wilkinson,
with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:
Resolution Low / High (Å)
|
89.53 /
1.70
|
Space group
|
P 21 21 21
|
Cell size a, b, c (Å), α, β, γ (°)
|
57.559,
121.881,
179.053,
90.00,
90.00,
90.00
|
R / Rfree (%)
|
20.7 /
25.8
|
Other elements in 5o4v:
The structure of P.Vivax Nmt with Aminomethylindazole and Quinoline Inhibitors Bound also contains other interesting chemical elements:
Magnesium Binding Sites:
The binding sites of Magnesium atom in the P.Vivax Nmt with Aminomethylindazole and Quinoline Inhibitors Bound
(pdb code 5o4v). This binding sites where shown within
5.0 Angstroms radius around Magnesium atom.
In total 3 binding sites of Magnesium where determined in the
P.Vivax Nmt with Aminomethylindazole and Quinoline Inhibitors Bound, PDB code: 5o4v:
Jump to Magnesium binding site number:
1;
2;
3;
Magnesium binding site 1 out
of 3 in 5o4v
Go back to
Magnesium Binding Sites List in 5o4v
Magnesium binding site 1 out
of 3 in the P.Vivax Nmt with Aminomethylindazole and Quinoline Inhibitors Bound
 Mono view
 Stereo pair view
|
A full contact list of Magnesium with other atoms in the Mg binding
site number 1 of P.Vivax Nmt with Aminomethylindazole and Quinoline Inhibitors Bound within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:Mg504
b:27.9
occ:1.00
|
N
|
A:LYS172
|
2.8
|
17.8
|
1.0
|
O
|
A:LEU169
|
2.9
|
16.9
|
1.0
|
O2A
|
A:NHW501
|
3.0
|
14.4
|
1.0
|
O5A
|
A:NHW501
|
3.0
|
15.8
|
1.0
|
N
|
A:LEU174
|
3.2
|
16.9
|
1.0
|
CA
|
A:LYS172
|
3.3
|
19.5
|
1.0
|
N
|
A:ARG173
|
3.4
|
18.9
|
1.0
|
CB
|
A:LYS172
|
3.4
|
19.4
|
1.0
|
C
|
A:LYS172
|
3.5
|
19.1
|
1.0
|
N
|
A:SER171
|
3.5
|
17.7
|
1.0
|
CB
|
A:LEU174
|
3.5
|
22.6
|
1.0
|
C
|
A:ARG170
|
3.7
|
15.6
|
1.0
|
P1A
|
A:NHW501
|
3.8
|
16.0
|
1.0
|
C
|
A:SER171
|
3.9
|
19.0
|
1.0
|
O1A
|
A:NHW501
|
3.9
|
14.0
|
1.0
|
CA
|
A:LEU174
|
3.9
|
18.5
|
1.0
|
C
|
A:LEU169
|
4.0
|
16.9
|
1.0
|
CG1
|
A:VAL165
|
4.0
|
14.5
|
1.0
|
CA
|
A:ARG170
|
4.0
|
17.2
|
1.0
|
CG
|
A:LEU174
|
4.1
|
28.2
|
1.0
|
CA
|
A:SER171
|
4.1
|
16.6
|
1.0
|
C
|
A:ARG173
|
4.2
|
18.7
|
1.0
|
CD1
|
A:LEU174
|
4.2
|
30.9
|
1.0
|
P2A
|
A:NHW501
|
4.2
|
17.2
|
1.0
|
CA
|
A:ARG173
|
4.3
|
18.4
|
1.0
|
O
|
A:LYS172
|
4.3
|
18.5
|
1.0
|
CG
|
A:LYS172
|
4.3
|
21.0
|
1.0
|
O
|
A:ARG170
|
4.3
|
18.9
|
1.0
|
O3A
|
A:NHW501
|
4.4
|
16.1
|
1.0
|
N
|
A:ALA175
|
4.5
|
16.5
|
1.0
|
N
|
A:ARG170
|
4.5
|
15.7
|
1.0
|
O6A
|
A:NHW501
|
4.7
|
17.5
|
1.0
|
C
|
A:LEU174
|
4.7
|
18.0
|
1.0
|
CB
|
A:VAL165
|
4.8
|
14.8
|
1.0
|
CG2
|
A:VAL165
|
4.9
|
14.0
|
1.0
|
CD
|
A:LYS172
|
4.9
|
22.1
|
1.0
|
O
|
A:SER171
|
5.0
|
19.9
|
1.0
|
|
Magnesium binding site 2 out
of 3 in 5o4v
Go back to
Magnesium Binding Sites List in 5o4v
Magnesium binding site 2 out
of 3 in the P.Vivax Nmt with Aminomethylindazole and Quinoline Inhibitors Bound
 Mono view
 Stereo pair view
|
A full contact list of Magnesium with other atoms in the Mg binding
site number 2 of P.Vivax Nmt with Aminomethylindazole and Quinoline Inhibitors Bound within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
B:Mg504
b:29.0
occ:1.00
|
O
|
B:LEU169
|
2.7
|
17.8
|
1.0
|
O5A
|
B:NHW501
|
2.9
|
16.5
|
1.0
|
O2A
|
B:NHW501
|
2.9
|
15.8
|
1.0
|
N
|
B:LYS172
|
3.0
|
18.5
|
1.0
|
N
|
B:LEU174
|
3.4
|
17.2
|
1.0
|
N
|
B:SER171
|
3.4
|
17.1
|
1.0
|
CB
|
B:LEU174
|
3.5
|
18.5
|
1.0
|
N
|
B:ARG173
|
3.5
|
16.7
|
1.0
|
CB
|
B:LYS172
|
3.6
|
18.4
|
1.0
|
CA
|
B:LYS172
|
3.6
|
17.9
|
1.0
|
C
|
B:LYS172
|
3.7
|
18.8
|
1.0
|
C
|
B:ARG170
|
3.8
|
19.6
|
1.0
|
P1A
|
B:NHW501
|
3.8
|
16.6
|
1.0
|
C
|
B:LEU169
|
3.8
|
17.9
|
1.0
|
CA
|
B:ARG170
|
3.9
|
18.4
|
1.0
|
O1A
|
B:NHW501
|
4.0
|
14.4
|
1.0
|
C
|
B:SER171
|
4.0
|
17.9
|
1.0
|
CG1
|
B:VAL165
|
4.0
|
19.1
|
1.0
|
CA
|
B:LEU174
|
4.0
|
17.0
|
1.0
|
P2A
|
B:NHW501
|
4.1
|
17.2
|
1.0
|
CD1
|
B:LEU174
|
4.1
|
22.6
|
1.0
|
CA
|
B:SER171
|
4.1
|
18.1
|
1.0
|
CG
|
B:LEU174
|
4.1
|
22.0
|
1.0
|
N
|
B:ARG170
|
4.3
|
19.0
|
1.0
|
O3A
|
B:NHW501
|
4.4
|
15.6
|
1.0
|
C
|
B:ARG173
|
4.4
|
18.6
|
1.0
|
CG
|
B:LYS172
|
4.4
|
19.7
|
1.0
|
CA
|
B:ARG173
|
4.5
|
16.7
|
1.0
|
N
|
B:ALA175
|
4.5
|
16.6
|
1.0
|
O
|
B:LYS172
|
4.5
|
19.9
|
1.0
|
O
|
B:ARG170
|
4.5
|
17.8
|
1.0
|
O6A
|
B:NHW501
|
4.6
|
17.6
|
1.0
|
CG2
|
B:VAL165
|
4.8
|
18.6
|
1.0
|
CB
|
B:VAL165
|
4.8
|
17.6
|
1.0
|
C
|
B:LEU174
|
4.8
|
16.8
|
1.0
|
CD
|
B:LYS172
|
4.9
|
26.7
|
1.0
|
|
Magnesium binding site 3 out
of 3 in 5o4v
Go back to
Magnesium Binding Sites List in 5o4v
Magnesium binding site 3 out
of 3 in the P.Vivax Nmt with Aminomethylindazole and Quinoline Inhibitors Bound
 Mono view
 Stereo pair view
|
A full contact list of Magnesium with other atoms in the Mg binding
site number 3 of P.Vivax Nmt with Aminomethylindazole and Quinoline Inhibitors Bound within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
C:Mg504
b:27.3
occ:1.00
|
O
|
C:LEU169
|
2.7
|
17.7
|
1.0
|
N
|
C:LYS172
|
2.8
|
21.0
|
1.0
|
O2A
|
C:NHW501
|
3.0
|
17.3
|
1.0
|
O5A
|
C:NHW501
|
3.1
|
16.1
|
1.0
|
N
|
C:LEU174
|
3.1
|
15.3
|
1.0
|
N
|
C:ARG173
|
3.3
|
18.0
|
1.0
|
CA
|
C:LYS172
|
3.4
|
19.8
|
0.5
|
CA
|
C:LYS172
|
3.4
|
20.2
|
0.5
|
C
|
C:LYS172
|
3.4
|
19.9
|
1.0
|
CB
|
C:LEU174
|
3.5
|
16.5
|
1.0
|
N
|
C:SER171
|
3.5
|
21.4
|
1.0
|
CB
|
C:LYS172
|
3.6
|
20.6
|
0.5
|
CB
|
C:LYS172
|
3.6
|
21.5
|
0.5
|
P1A
|
C:NHW501
|
3.8
|
17.4
|
1.0
|
CA
|
C:LEU174
|
3.8
|
15.6
|
1.0
|
O1A
|
C:NHW501
|
3.9
|
18.6
|
1.0
|
C
|
C:ARG170
|
3.9
|
20.9
|
1.0
|
C
|
C:LEU169
|
3.9
|
18.4
|
1.0
|
C
|
C:SER171
|
3.9
|
22.2
|
1.0
|
CG
|
C:LEU174
|
4.0
|
17.1
|
1.0
|
CA
|
C:ARG170
|
4.1
|
19.3
|
1.0
|
CD1
|
C:LEU174
|
4.1
|
16.9
|
1.0
|
CA
|
C:SER171
|
4.1
|
20.0
|
1.0
|
CG1
|
C:VAL165
|
4.1
|
14.1
|
1.0
|
C
|
C:ARG173
|
4.1
|
18.0
|
1.0
|
P2A
|
C:NHW501
|
4.2
|
16.2
|
1.0
|
O
|
C:LYS172
|
4.2
|
19.0
|
1.0
|
CA
|
C:ARG173
|
4.2
|
17.6
|
1.0
|
N
|
C:ALA175
|
4.3
|
14.5
|
1.0
|
O3A
|
C:NHW501
|
4.4
|
16.4
|
1.0
|
CG
|
C:LYS172
|
4.4
|
19.9
|
0.5
|
N
|
C:ARG170
|
4.5
|
18.3
|
1.0
|
CG
|
C:LYS172
|
4.5
|
21.5
|
0.5
|
O
|
C:ARG170
|
4.5
|
24.4
|
1.0
|
C
|
C:LEU174
|
4.6
|
15.9
|
1.0
|
O6A
|
C:NHW501
|
4.7
|
18.1
|
1.0
|
CB
|
C:VAL165
|
4.9
|
14.3
|
1.0
|
CG2
|
C:VAL165
|
4.9
|
16.0
|
1.0
|
|
Reference:
A.Mousnier,
A.S.Bell,
D.P.Swieboda,
J.Morales-Sanfrutos,
I.Perez-Dorado,
J.A.Brannigan,
J.Newman,
M.Ritzefeld,
J.A.Hutton,
A.Guedan,
A.S.Asfor,
S.W.Robinson,
I.Hopkins-Navratilova,
A.J.Wilkinson,
S.L.Johnston,
R.J.Leatherbarrow,
T.J.Tuthill,
R.Solari,
E.W.Tate.
Fragment-Derived Inhibitors of Human N-Myristoyltransferase Block Capsid Assembly and Replication of the Common Cold Virus. Nat Chem V. 10 599 2018.
ISSN: ESSN 1755-4349
PubMed: 29760414
DOI: 10.1038/S41557-018-0039-2
Page generated: Sun Sep 29 23:47:13 2024
|